Vitality Biopharma (OTCMKTS:VBIO) and Medpace (NASDAQ:MEDP) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their profitability, risk, institutional ownership, earnings, valuation, dividends and analyst recommendations.
This table compares Vitality Biopharma and Medpace’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
This is a breakdown of recent ratings and target prices for Vitality Biopharma and Medpace, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Medpace has a consensus price target of $58.00, indicating a potential upside of 2.75%. Given Medpace’s higher probable upside, analysts plainly believe Medpace is more favorable than Vitality Biopharma.
Valuation and Earnings
This table compares Vitality Biopharma and Medpace’s top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Vitality Biopharma||$100,000.00||106.07||-$4.30 million||N/A||N/A|
|Medpace||$704.59 million||2.87||$73.18 million||$2.59||21.80|
Medpace has higher revenue and earnings than Vitality Biopharma.
Institutional and Insider Ownership
77.5% of Medpace shares are owned by institutional investors. 8.7% of Vitality Biopharma shares are owned by company insiders. Comparatively, 24.2% of Medpace shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Volatility and Risk
Vitality Biopharma has a beta of 1.4, suggesting that its stock price is 40% more volatile than the S&P 500. Comparatively, Medpace has a beta of 1.51, suggesting that its stock price is 51% more volatile than the S&P 500.
Medpace beats Vitality Biopharma on 10 of the 11 factors compared between the two stocks.
Vitality Biopharma Company Profile
Vitality Biopharma, Inc. engages in the development of cannabinoid pharmaceuticals for the treatment of neurological and inflammatory disorders in the United States. The company's products in pipeline include VBX-100, an oral cannabinoid formulation for inflammatory bowel disease, C.difficile-associated diarrhea and colitis, and narcotic bowel syndrome; and VBX-210, a cannabinoid formulation, which is in preclinical studies for the treatment of gastrointestinal conditions. It develops additional cannabinoid product formulations for refractory pain and autism spectrum disorder. The company was formerly known as Stevia First Corp. and changed its name to Vitality Biopharma, Inc. in July 2016. The company was founded in 2007 and is based in Los Angeles, California.
Medpace Company Profile
Medpace Holdings, Inc., a clinical contract research organization, provides scientifically-driven outsourced clinical development services to the biotechnology, pharmaceutical, and medical device industries worldwide. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in a range of therapeutic areas. Its drug development services include development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support. The company also provides bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. Medpace Holdings, Inc. was founded in 1992 and is headquartered in Cincinnati, Ohio.
Receive News & Ratings for Vitality Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vitality Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.